Dendritic cell immunotherapy for malignant gliomas
/in Dendritic Cells, Glioblastoma, International PublicationsA phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors
/in Dendritic Cells, Gallbladder Cancer, International Publications, Pancreatic CancerCopulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation
/in Dendritic Cells, International PublicationsHuman papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial
/in Cervical Cancer, Dendritic Cells, International Publications[Effects of intratumoral injection therapy of dendritic cells combined with hyperthermia for cancer patients]
/in Dendritic Cells, International PublicationsPhase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides
/in Dendritic Cells, International Publications, Multiple Myeloma[Dendritic cells pulsed with glioma RNA induce immunity against intracranial gliomas]
/in Dendritic Cells, Glioblastoma, International PublicationsThe ‚kiss of death‘ by dendritic cells to cancer cells
/in Dendritic Cells, International PublicationsNumerical and functional defects of blood dendritic cells in early- and late-stage breast cancer
/in Breast Cancer, Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer